Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06710847 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

A Phase 1 study of Solid Tumor and Endometrial Cancer, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 1
Development phase
14
Enrollment target
20
Study locations

NCT06710847: Active Phase 1 study of Solid Tumor and Endometrial Cancer, sponsored by GlaxoSmithKline.

NCT06710847 is a Phase 1 study of Solid Tumor and Endometrial Cancer that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 14 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06710847, a Phase 1 study of Solid Tumor and Endometrial Cancer, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
14 participants
Enrollment target
20
Study locations

Study Summary

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.

Conditions Studied

Solid Tumor Endometrial Cancer Colon Cancer Rectal Cancer Neoplasms, Colorectal

Interventions

  • DRUG GSK4418959
  • BIOLOGICAL PD-1 inhibitor

Study Locations (20)

Other

  • GSK Investigational Site - Brussels
  • GSK Investigational Site - Ghent
  • GSK Investigational Site - Leuven
  • GSK Investigational Site - Chiba
  • GSK Investigational Site - Shizuoka
  • GSK Investigational Site - Tokyo
  • GSK Investigational Site - Tokyo
  • GSK Investigational Site - Amsterdam
  • GSK Investigational Site - Daegu
  • GSK Investigational Site - Gyeonggi-do
  • GSK Investigational Site - Seoul
  • GSK Investigational Site - Barcelona
  • GSK Investigational Site - Barcelona

Pennsylvania

  • GSK Investigational Site - Philadelphia
  • GSK Investigational Site - Philadelphia

California

  • GSK Investigational Site - Los Angeles

Colorado

  • GSK Investigational Site - Denver

Michigan

  • GSK Investigational Site - Detroit

New York

  • GSK Investigational Site - New York

Victoria

  • GSK Investigational Site - Melbourne

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2024-12-13
Est. Completion 2026-06-22
Phase Phase 1
GlaxoSmithKline

1,345 total trials

What the registry record for NCT06710847 still lists

NCT06710847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (94% lower).

The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which GSK4418959 is the first listed.

NCT06710847 names 20 study sites across 7 states, led by Other, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT06710847 about?

NCT06710847 is a clinical study titled "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors". Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 i...

What is the current status of trial NCT06710847?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-12-13. Estimated completion is 2026-06-22.

What conditions does trial NCT06710847 study?

This clinical trial studies the following conditions: Solid Tumor, Endometrial Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Colorectal.

What interventions are being tested in trial NCT06710847?

The interventions under investigation include: GSK4418959 (DRUG), PD-1 inhibitor (BIOLOGICAL).

Who is sponsoring clinical trial NCT06710847?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06710847 being conducted?

This trial has 20 study locations across California, Colorado, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06710847's enrollment target sits among peer trials

14 185th of 196 higher than 9 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Related registry views

Source: ClinicalTrials.gov NCT06710847, the US trial registry maintained by the National Library of Medicine. NCT06710847 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.